ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-18 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 275.6 KB | ||
| 2021-01-21 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 657.3 KB | ||
| 2021-01-21 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2020.
|
French | PDF • 536.3 KB | ||
| 2021-01-05 19:00 |
ABIVAX PUBLIE DANS « DRUG DISCOVERY TODAY » UN ARTICLE SUR LE MECANISME D'ACTIO…
|
French | PDF • 234.0 KB | ||
| 2021-01-05 19:00 |
ABIVAX PUBLISHES REVIEW IN DRUG DISCOVERY TODAY ON MECHANISM OF ACTION AND TRAN…
|
English | HTML • 13.3 KB | ||
| 2020-12-22 19:30 |
L'essai de phase 2b/3 d'ABX464 « miR-AGE » dans la Covid-19 déclaré « Priorité …
|
French | PDF • 222.3 KB | ||
| 2020-12-22 19:30 |
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research Nation…
|
English | HTML • 14.0 KB | ||
| 2020-12-22 18:28 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 275.2 KB | ||
| 2020-12-21 18:30 |
ABIVAX: A l'approche d'étapes cliniques majeures, Abivax est retenu pour une pr…
|
French | PDF • 205.4 KB | ||
| 2020-12-21 18:30 |
Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of…
|
English | HTML • 11.6 KB | ||
| 2020-12-09 19:46 |
Abivax establishes clinical, regulatory and manufacturing framework for ABX464 …
|
English | HTML • 13.8 KB | ||
| 2020-12-09 19:45 |
Abivax complète ses plans cliniques, réglementaires et industriels en préparati…
|
French | PDF • 236.1 KB | ||
| 2020-12-03 18:00 |
Abivax calendrier de communication financière 2021
|
French | PDF • 167.5 KB | ||
| 2020-12-03 18:00 |
Abivax 2021 Financial Communication Calendar
|
English | HTML • 6.4 KB | ||
| 2020-11-30 19:00 |
Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative c…
|
English | HTML • 16.2 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
